Loading
Deliver engineered T cells directly into the chest cavity where mesothelioma grows, and give immunotherapy to keep them working.
This idea would infuse mesothelin-directed CAR-T cells directly into the pleural cavity of patients with relapsed mesothelioma and add PD-1 blockade to keep the cells working. Mesothelin is expressed on almost all mesotheliomas, the pleural space is accessible, regional delivery avoids on-target lung toxicity, and in preclinical models CAR-T exhaustion is reversible with checkpoint blockade. A phase 1 study at Memorial Sloan Kettering Cancer Center led by Adusumilli combined intrapleural CAR-T with pembrolizumab and produced responses and some long survivors. The next step is a phase 2 with a second-line control and an armoured CAR-T arm; at an early clinical stage, it addresses the bottleneck of cold tumours and the idea of treating the body cavity rather than the bloodstream.
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Mesothelin Immunotherapy for Cancer: Ready for Prime Time?, Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors, Mesothelin: a new target for immunotherapy, Mesothelin.
Shares Armoured, logic-gated & next-gen CARs, Mesothelioma, CAR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, Cold tumours and the immunosuppressive microenvironment, CAR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Mesothelin, Mesothelioma.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.